Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Single Arm-Studies suggest improved remission and survival rates for a Protocol with
Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a
conventional DA 7+3 protocol (45mg/m2 Daunorubicin).